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Background: Many probiotic bacteria have been described as promising tools for the treatment and prevention of
inflammatory bowel diseases (IBDs). Most of these bacteria are lactic acid bacteria, which are part of the healthy
human microbiota. However, little is known about the effects of transient bacteria present in normal diets, including
Lactococcus lactis.
Methods: In the present study, we analysed the immunomodulatory effects of three L. lactis strains in vitro using
intestinal epithelial cells. L. lactis NCDO 2118 was administered for 4 days to C57BL/6 mice during the remission period
of colitis induced by dextran sodium sulphate (DSS).
Results: Only one strain, L. lactis NCDO 2118, was able to reduce IL-1β-induced IL-8 secretion in Caco-2 cells, suggesting
a potential anti-inflammatory effect. Oral treatment using L. lactis NCDO 2118 resulted in a milder form of recurrent
colitis than that observed in control diseased mice. This protective effect was not attributable to changes in secretory
IgA (sIgA); however, NCDO 2118 administration was associated with an early increase in IL-6 production and sustained
IL-10 production in colonic tissue. Mice fed L. lactis NCDO 2118 had an increased number of regulatory CD4+ T cells
(Tregs) bearing surface TGF-β in its latent form (Latency-associated peptide-LAP) in the mesenteric lymph nodes
and spleen.
Conclusions: Here, we identified a new probiotic strain with a potential role in the treatment of IBD, and we
elucidated some of the mechanisms underlying its anti-inflammatory effect.
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Inflammatory bowel diseases (IBDs), such as ulcerative
colitis (UC) and Crohn’s disease (CD), have very complex
causes that involve genetic, environmental and geographic
factors [1]. They are thought to result from inappropriate
and ongoing activation of the mucosal immune cells* Correspondence: afaria@icb.ufmg.br; miysohi@icb.ufmg.br
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unless otherwise stated.driven by the presence of an abnormal gut microbiota,
resulting in chronic inflammation of the gastrointestinal
tract (GIT) [2]. It has been shown that infiltrating T lym-
phocytes responsive to the gut microbiota are associated
with a loss of tolerance in the intestinal mucosa [3].
Current IBD treatments include anti-inflammatory
drugs, which induce or maintain remission, but are not
curative. Moreover, their use is accompanied by several
side effects such as allergic reactions, chills, fever, urti-
caria and liver problems [4,5]. In this context, biologic
agents, such as probiotics with anti-inflammatory prop-
erties, have been proposed as tools for both the preven-
tion and treatment of IBD [6].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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to the lactic acid bacteria (LAB) group and are mainly
composed of lactobacilli, which have been isolated from
the human GIT. However, probiotics may also include
some Bifidobacterium [7] and Streptococcus strains [8].
Members of the Lactobacillus genus have therapeutic
properties, such as improvement of the normal micro-
biota [9,10], prevention of infectious diseases and food
allergies [11-13], stabilisation of the gut mucosal barrier
[14,15] and modulation of innate and adaptive immune
responses [16-20].
On the other hand, the Lactococcus genus has received
little attention with respect to its probiotic activities,
mainly because these bacteria are not usually considered
to be commensal [21]. However, Lactococcus lactis
strains are in constant transit through the GIT after
ingestion of fermented dairy and vegetable products, and
a few studies have shown that they can exert beneficial
effects [20]. Among these, Nishitani et al. [22] demon-
strated that L. lactis subsp. cremoris FC possess potent
anti-inflammatory activity. Oral administration of L. lactis
FC reduced inflammatory cytokine production as well as
inducible nitric oxide expression in dextran sulphate so-
dium (DSS)-induced colitis in mice, suggesting that orally
administered L. lactis FC may have a beneficial impact in
human IBD [22]. Thus, the objective of this study was to
evaluate the potential mechanisms involved in the anti-
inflammatory effects of L. lactis strains that are still poorly
understood.
Results
Anti-inflammatory effect of L. lactis on intestinal epithelial
cells (IECs) is strain-dependent
None of the tested L. lactis strains induced IL-8 secretion
above background levels, indicating that they do notFigure 1 IL-8 levels after co-incubation of L. lactis strains with Caco-2
of IL-1β or bacteria; IL-1β, only IL-1β was added; GM17, only the medium w
experiments. *, p < 0.05.induce inflammatory events in IECs (Figure 1A and B). To
investigate whether L. lactis has an anti-inflammatory ef-
fect on IECs, the ability of the strains to block IL-8 secre-
tion induced by IL-1β was analysed. Caco-2 cells secreted
baseline levels of IL-8, which increased after stimulation
with IL-1β. None of the live cell fractions were able to re-
duce IL-1β-induced IL-8 secretion (Figure 1A); however,
the supernatant of NCDO 2118 cultures reduced the pro-
duction of IL-8 by 45% (Figure 1B), whereas the other 2
supernatants did not show similar effects. Thus, the anti-
inflammatory role of L. lactis in vitro is strain-dependent.
Oral administration of L. lactis NCDO 2118 alleviates
colitis symptoms
Based on our in vitro results, L. lactis NCDO 2118 was
then selected for testing in vivo. The effect of oral ad-
ministration of this strain was tested in a murine model
of chemically induced colitis during the remission period
and after a second colitis cycle. This experimental proto-
col mimics the remission and active periods of IBD. As
shown in Figure 2B, the body weight of mice signifi-
cantly decreased during DSS treatment compared to the
body weight of water-treated mice (control group). After
DSS withdrawal, the mice gradually recovered their body
weight in all experimental groups. Treatment with L.
lactis NCDO 2118 did not contribute to a significant
change in weight gain (Figure 2B). A reduction in colon
length at day 14 in the DSS and DSS +NCDO2118
groups was also observed (Figure 2C). Nevertheless, at
the end of the experiment on day 21, oral treatment with
L. lactis led to the restoration of colon length (Figure 2C).
Mice consuming L. lactis exhibited significantly reduced
clinical symptoms (macroscopic inflammatory score) in
the recovery phase and upon colitis induction (Figure 2D),
despite the severity of inflammation after the second colitiscells. (A) L. lactis cells. (B) L. lactis supernatant. Dash, without addition
as added. Bars represent the mean and the MSE of three independent
Figure 2 Oral administration of L. lactis NCDO 2118 improved colon shortening and macroscopic score of colitis. (A) Experimental
protocol. C57BL/6 mice received 2% DSS for 7 days. L. lactis NCDO 2118 was continually administered for 4 consecutive days during the
remission period of colitis (arrows) between the first and second course of colitis. The control group received medium. Mice were sacrificed
at days 14 and 21 (arrowheads). (B) Body weight from day 0 to day 21. (C) Colon length measured in cm. (D) Macroscopic score of colitis,
including scores related to body weight, diarrhea and rectal bleeding. Bars are the mean of 6 mice/group, and the data are representative
of three independent experiments; ANOVA, Tukey post-test. *, p < 0.05, **, p < 0.01, ***, p < 0.001.
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administered in vivo has an anti-inflammatory effect.
L. lactis NCDO 2118 prevents intestinal inflammation
The ability of L. lactis NCDO 2118 to prevent DSS-
induced colonic damage was evaluated at the histological
level. Colon sections from mice of the control group
had an intact epithelium, a well-defined crypt length,
and no neutrophil infiltration in the mucosal and sub-
mucosal layers (Figure 3A). In contrast, colon tissues
from DSS-treated mice showed severe inflammatory le-
sions throughout the mucosa and submucosa (Figure 3B).
Oral administration of L. lactis NCDO 2118 ameliorated
the histological damage after the second colitis cycle but
did not immediately improve the inflammatory status of
the gut mucosa on day 14 (Figure 3C, D).
L. lactis NCDO 2118 did not alter secretory IgA production
Secretory IgA was evaluated in mouse faeces at days 14
and 21. The levels of sIgA were increased only after the
second colitis cycle. Oral administration of L. lactis
NCDO 2118 maintained sIgA production at intermedi-
ate levels (Figure 4A). To verify whether L. lactis was
able to modify the sIgA levels in a physiological scenario,we measured sIgA levels after 2, 3 or 4 days of oral ad-
ministration of L. lactis. L. lactis NCDO 2118 did not
alter sIgA production (Figure 4B), discarding the possi-
bility that IgA modulation might be a regulatory mech-
anism mediated by L. lactis.
L. lactis NCDO 2118 modulates the production of
cytokines in intestinal tissue
To further identify potential mechanisms by which L.
lactis NCDO 2118 exerts its beneficial effects, cytokine
profiles in colonic tissue were evaluated at days 14 and
21. Oral administration of NCDO2118 significantly in-
creased the levels of IL-6 at day 14, while the levels of
this cytokine were higher at day 21 in both DSS- and
DSS +NCDO2118-treated groups (Figure 5A). The expos-
ure of C57BL/6 to 2% DSS led to increased IL-12 levels
only at day 21, and L. lactis did not affect this phenomenon
(Figure 5B). Despite this, the levels of IFN-γ did not
change due to DSS or L. lactis treatment (Figure 5C).
IL-17 levels were reduced at day 21 in both the DSS and
DSS + NCDO2118 groups (Figure 5D). TGF-β was not
affected by DSS or L. lactis (Figure 5E). The anti-
inflammatory cytokine IL-10 was significantly decreased in
the DSS-treated group but not in the NCDO 2118-treated
Figure 3 Oral administration of L. lactis NCDO 2118 prevented histological damage induced by colitis. Photograph (X100) of H&E-stained
paraffin sections of a representative colon from control (A), DSS (B) and DSS + NCDO2118 (C) groups at day 21. (D) Histological scores of colon
sections of DSS-colitis mice with or without oral administration of L. lactis. Values represent the means ± MSE (n = 6). **, p < 0.01, ***, p < 0.001.
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increased in DSS-treated mice at day 14, while the TNF-α
level in the NCDO 2118-treated mice was maintained at a
level similar to that of the control group.L. lactis NCDO 2118 affects cells involved in tolerance
Because the intestinal inflammation in DSS-induced col-
itis is triggered by microbial antigens, induction of oral
tolerance to microbiota could be one of the potential
mechanisms by which L. lactis NCDO 2118 stimulates
the immune system. Because oral tolerance is maintained
mainly by Treg cells [23], we analysed the changes in
CD4+CD25+CD45RBlow and CD4+CD25+LAP+ T cells
in the mesenteric lymph nodes and spleens of mice. L.
lactis NCDO 2118 did not alter the numbers of acti-
vated T cells in mesenteric lymph nodes. However, this
treatment enhanced the number of activated T cells
(CD69+) in the spleen (Figure 6A), suggesting that some
L. lactis products are able to activate T cells in vivo. The
population of CD4+CD25+CD45RBlow regulatory T cells
was not affected by DSS or DSS-NCDO2118 treatment
(Figure 6B). The same result was observed for CD4+Foxp3+
Tregs (data not shown). Nevertheless, the levels of
CD4+CD25+LAP+ regulatory T cells were increased in
the mesenteric lymph nodes and spleens of NCDO
2118-treated mice.Increase in the frequency of tolerogenic dendritic cells
(DCs) in the group treated with L. lactis
The DC population described as tolerogenic alphaE-
beta7-(CD103)-expressing DCs was analysed in the
mesenteric lymph nodes and spleen. We did not find
differences in CD11c+CD11b−CD103+ cells in mesen-
teric lymph nodes. However, the frequencies of these
cells were increased in the spleen during colitis (DSS
group), and they were further enhanced in mice of the
DSS + NCDO2118 group.
Discussion
In this study, we showed that culture supernatants of L.
lactis NCDO 2118 were able to reduce IL-8 production
by Caco-2 cells stimulated with IL-1β. Thus, the L. lactis
NCDO 2118 strain has an immunomodulatory effect in
IECs in vitro. This conclusion is based on the previous
finding that IL-1β triggers transcriptional activation of
pro-inflammatory genes in intestinal epithelial cells (IECs),
such as IL-8, TNF-α, IL-6, cyclooxygenase-2 (Cox-2) and
many others [24,25].
Expression of IL-8 has been shown that this transcrip-
tional factor is overactivated in mucosal cells of IBD
patients [26], thus, the search for alternative treatment
against IBD, the ability to inhibit the IL-8 secretion or
its pathway of production is a good parameter to be
considered [27]. Several probiotics, mainly commensals,
Figure 4 Oral administration of L. lactis NCDO 2118 did not
alter secretory IgA production. (A) Intestinal faeces were collected
and total sIgA was measured by ELISA in mice from control, DSS and
DSS +NCDO2118 groups. (B) Intestinal faeces from healthy mice were
collected after 2, 3 or 4 days of L. lactis administration, and total sIgA
was measured by ELISA. Bars represent the mean ±MSE of 5 mice per
group. **, p < 0.01.
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reuteri [29], and Bifidobacterium longum [29] influence
downstream cytokine secretion IL-8 in IECs, while for
L. lactis, little has been published. Co-cultures of L. lactis
subsp. cremoris FC with Caco-2 cells resulted in signifi-
cant down-regulation of IL-8 mRNA expression in Caco-2
cells and inhibition of NF-κB nuclear translocation in
RAW264.7 cells [22]. Interestingly, we found that IL-8
inhibition is dependent on the strain used for the assay.
Similar results were reported by Santos Rocha et al. [20].
They also found a strain-dependent immunomodulatory
effect by the dairy bacteria Lactobacillus delbrueckii [20].
In this study, we showed using an in vitro assay that
L. lactis NCDO 2118 strain has an immunomodulatory
effect in IECs. This conclusion is based on the fact
that IL-1β triggers transcriptional activation of pro-
inflammatory genes in IECs. Thus, IL-1β activates
transcription factors, including nuclear factor κB (NF-κB),
which induces increased expression of pro-inflammatory
mediators, such as IL-8, TNF-α, IL-6, cyclooxygenase-2
(Cox-2) and many others [24,25].
Due to these interesting in vitro results, L. lactis
NCDO 2118 appears to have a potential use as aprobiotic for IBD therapy. Thus, in vivo experiments
were performed to evaluate the effectiveness of this
strain in a DSS-induced murine model of colitis.
We have shown that L. lactis NCDO 2118 was able
to ameliorate a second colitis cycle induced by DSS. In
our study, intestinal injury was assessed by a variety of
methods, including body weight, colon length and hist-
ology. Based on macroscopic and microscopic criteria,
L. lactis NCDO 2118 inhibited colonic injury. The ex-
perimental time period resembles the typical remission
period of IBD. We chose to administer the bacteria after
the onset of colitis to more closely resemble a clinical
scenario, as it is not possible to predict when the disease
will start or when it will became active.
L. lactis NCDO 2118 also improved the macroscopic
symptoms of colitis, especially diarrhea at day 14. How-
ever, at this time point, colon length and histological
signs were not ameliorated. The analysis of two time
points (at day 14 and 21) allowed us to separate two differ-
ent scenarios in which L. lactis exerted effects. We opted
to investigate the second scenario because colitis improve-
ment was more evident after the second cycle of colitis.
Several studies have shown that consumption of pro-
biotics is associated with increased gut sIgA levels,
which could promote the integrity of the gut immuno-
logical barrier by limiting the penetration of bacteria
(commensal and pathogenic) into host tissues [30,31].
This is particularly relevant in the DSS model of colitis
because DSS is toxic to gut epithelial cells and enhances
bacterial translocation [32,33]. However, L. lactis did not
alter sIgA production after oral treatment.
Cytokines produced in the gut mucosa greatly influence
the resulting immunological outcome. The production of
anti-inflammatory cytokines induces mucosal tolerance,
and high levels of pro-inflammatory cytokines induce a
protective immune response and inflammation. The most
intriguing aspect of probiotic-induced modulation of im-
mune responses is the effect of probiotics on cytokine
production. Few studies have investigated the effect of L.
lactis NCDO 2118 on cytokine production. Kimoto et al.
[34] showed that L. lactis G50 induces Th1-type immune
responses in vitro. Pavan et al. [35] observed a significant
increase in IFN-γ production in the ilea of mice fed L.
lactis MG1363. In our study, L. lactis NCDO 2118 did
not alter the production of IFN-γ in colonic tissue.
We found increased levels of IL-6 in the colon of mice
fed L. lactis NCDO 2118 after colitis induction. In acute
situations, such as chemically induced colitis, IL-6-deficient
mice had higher levels of inflammation than wild type
mice. It appears that IL-6 enhances mucosal repair by epi-
thelial reconstitution [36-40]. Therefore, we speculate that
L. lactis could promote epithelial repair via IL-6 production
resulting ultimately in the prevention of diarrhea as
discussed above.
Figure 5 Effect of L. lactis NCDO 2118 on cytokine production by colonic cells. Colonic IL-6 (A), IL-12 (B), IFN-γ (C), IL-17 (D), TGF-β (E),
IL-10 (F) and TNF-α (G) were measured by ELISA in mice from control, DSS and DSS + NCDO2118 groups. One representative result from
two independent repetitions is shown. Bars represent the mean ± MSE of 5 mice per group. *, p < 0.05, **, p < 0.01, ***, p < 0.001.
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role in the intestine [41]. However, neutralisation of IL-17
can aggravate acute DSS-induced colitis in mice, suggest-
ing that IL-17 has a protective role in colonic inflamma-
tion [42]. In our study, IL-17 levels were diminished in
mice that received the second cycle of DSS, but these
levels were not affected by oral administration of L. lactis
NCDO 2118.
IL-10 is most likely the most important cytokine in-
volved in shaping immune responses at the gut mucosa.
IL-10-deficient mice spontaneously develop gut inflam-
mation [43]. In the present study, after the second cycle
of colitis, IL-10 levels were decreased in the colon of
DSS-treated mice, but L. lactis NCDO 2118 administra-
tion prevented this reduction. Thus, the maintenance of
IL-10 levels seems to be responsible, at least in part, for
the anti-inflammatory effect of L. lactis NCDO 2118.
In the present study, the oral administration of L. lactis
NCDO 2118 improved the aberrant levels of TNF-αinduced by DSS approximately to the control levels. In
agreement with this, Nishitani et al. [22] demonstrated
that Lactococcus lactis cremoris drastically reduced the
mRNA expression of TNF-α, the major proinflammatory
cytokine involved in the DSS-induced colitis model.
To investigate the effect of L. lactis on Tcell populations,
we evaluated these cells in the mesenteric lymph nodes
and spleens of mice treated or not with L. lactis NCDO
2118 during chronic colitis. IBD is generally believed to be
driven by T cells and has been thought to be associated
with an increase in inflammatory cytokines, especially
from Th1 and Th17 cells. Specialised regulatory T cells
counterbalance these proinflammatory responses [44,45].
The numbers of activated T cells expressing the earliest in-
ducible cell surface glycoprotein acquired during lymphoid
activation, CD69, were analysed after colitis induction. The
numbers of CD4+CD69+ T cells were increased only in the
spleens of mice fed L. lactis NCDO 2118. Therefore, some
L. lactis products were able to activate T cells.
Figure 6 Effect of L. lactis NCDO 2118 on T cells and tolerogenic dendritic cells. The numbers of activated T cells, regulatory T cells and
tolerogenic dendritic cells in chemically induced colitis were determined in the mesenteric lymph nodes (mLNs) and spleen; the cells were stained at
day 21. (A) Number of CD4 + CD69+ T cells. (B) CD4 + CD25 + CD45RBlow T cells. (C) CD4 + CD25 + LAP + T cells. (D) CD11c + CD11b-CD103+ cells. Bars
are the mean of 5 mice/group, and the data are representative of two independent experiments; ANOVA, Tukey post-test. **, p < 0.01, ***, p < 0.001.
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vation in leukopenic mice have been reported to induce
colitis, whereas co-transfer of CD4+CD25+CD45RBlow T
cells can prevent disease induction [46]. This T cell
population was further identified as a regulatory T cell
subset. Despite the anti-inflammatory activity of L. lactis
NCDO 2118, its administration did not enhance the
frequency of this regulatory T cell population. However,
another type of peripherally induced Treg cells charac-
terised by their surface expression of LAP, which is the
N-terminal propeptide of TGF-beta precursor, were in-
creased in the mesenteric lymph nodes and spleens ofmice treated with L. lactis NCDO 2118. Previously, Di
Giacinto et al. [17] showed that administration of the pro-
biotic VSL#3 during the remission period of TNBS-induced
colitis increases the numbers of regulatory CD4+LAP+ T
cells, and this is essential to the protective effect of the
probiotic.
Because dendritic cells modulate T cell differentiation
into effector or regulatory T cells [47], the profile of
DCs was evaluated. It has been shown previously that
CD103+ DCs can induce CD4 + CD25 + Foxp3+ Treg
cells in the intestinal mucosa [48]. In the chemically
induced colitis model, we found increased numbers of
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oral administration of L. lactis NCDO 2118 enhanced the
numbers of CD11c+CD103+ DCs to a greater extent. Gyu
Jeon et al. [49] recently showed that Bifidobacterium breve
induced the development of IL-10-producing T cells and
that this effect was mediated by CD103+ DCs. Thus, L.
lactis NCDO 2118 may trigger a regulatory phenotype in
DCs that drives the expansion of induced regulatory T
cells such as CD4+LAP+. Therefore, we propose a working
model for L. lactis NCDO 2118 activity in vivo, which is
depicted in Figure 7.
Conclusions
In conclusion, we showed that L. lactis NCDO 2118 has
anti-inflammatory activity in an in vitro culture of intes-
tinal epithelial cells (IECs) and in a DSS-induced model
of colitis. Moreover, we showed the effectiveness of this
in vitro screening method for identification of a probiotic
strain of L. lactis that can be further tested in vivo. The
mechanisms involved in such anti-inflammatory effects
include modulation of colonic cytokines as well as expan-
sion of regulatory T cells and anti-inflammatory DCs.
Taken together, our results suggest that not only com-
mensal but also dairy bacteria that are part of our diet can
have probiotic effects. The nature of the L. lactis NCDO
2118 components that are responsible for its anti-
inflammatory effects is under investigation.
Methods
Ethics statement
Conventional inbred female C57BL/6 mice, 10 to 12 weeks
of age, were obtained from Universidade Federal de Minas
Gerais (UFMG), Brazil. Mice were maintained in anFigure 7 Schematic model for the immunomodulatory effects of Lactoc
Lactococcus lactis NCDO 2118 is able to induce an early increase in IL-6 pro
sulphate sodium (DSS)-induced murine model of ulcerative colitis. It also increa
These cells migrate to the mesenteric lymph nodes and stimulate the ex
leading ultimately to downmodulation of colitis.environmentally controlled room with 12 h light–dark
cycle. All procedures were approved by the local ethics
committee for animal research (Comitê de Ética em Experi-
mentação Animal (CETEA) from Universidade Federal
de Minas Gerais (UFMG), Brazil- CEUA # 114/2010).
Bacterial strains and growth conditions
Three L. lactis strains were used in this study: L. lactis
subsp. lactis NCDO 2118 [50], L. lactis subsp. lactis
IL1403 [51], and L. lactis subsp. cremoris MG1363 [52].
They were grown at 30°C in M17 medium (Difco) con-
taining 0.5% glucose (GM17) without agitation or in the
same medium solidified with 1.5% agar for 18 hours.
Epithelial cell culture
Caco-2 cells (ATCC HTB-37), a human colon adenocar-
cinoma cell line, were cultured in RPMI medium
(Sigma) supplemented with 10% (v/v) of fetal bovine
serum (FBS) (Gibco), 2 mM L-glutamine, 0.1 mM non-
essential amino acids, and 1 mM sodium pyruvate solu-
tion in an atmosphere containing 5% CO2 at 37°C.
Epithelial cell treatments
Caco-2 cells were seeded at 3×105 cells/well in 24-well
plates and incubated at 37°C with 5% CO2 for 24 hours
before treatment. Secretion of the pro-inflammatory
cytokine IL-8 by the cells was induced by the addition of
human recombinant IL-1β (BD Biosciences) to a final
concentration of 10 ng/mL. L. lactis cultures in the sta-
tionary phase of growth were fractionated by centrifuga-
tion into supernatant and cells, and each fraction was
co-incubated with Caco-2 cells. Bacterial cells were
washed 2 times with PBS (137 mM/L NaCl, 2.7 mM/Loccus lactis NCDO 2118 in DSS-induced colitis. Orally administered
duction and to sustain IL-10 secretion in colonic tissue of the dextran
ses the number of local tolerogenic dendritic cells (CD11c+CD11b−CD103+).
pansion of CD4+CD25+LAP+ cells, a regulatory type of T cell (Treg),
Luerce et al. Gut Pathogens 2014, 6:33 Page 9 of 11
http://www.gutpathogens.com/content/6/1/33KCl, 10 mM/L Na2HPO4 • 2 H2O, 2 mM/L KH2PO4)
and added at a multiplicity of infection (MOI) of 5. The
supernatant was filtered at a final concentration of 10%
(v/v). Caco-2 cells that were not treated with IL-1β were
used as controls. After 6 hours of co-incubation, the
supernatant of cell cultures was collected and stored
at −80°C until analysis. IL-8 levels were measured using
a Human IL-8 ELISA Kit (BD Biosciences) following the
manufacturer's instructions. Data from three independ-
ent experiments were analysed.
DSS-induced colitis
Chemical colitis was induced by replacing the drinking
water of mice with a 2% (w/v) aqueous solution of dextran
sodium sulphate (DSS, MP Biomedicals) for 7 consecutive
days. Subsequently, mice received either GM17 medium
(DSS group) or L. lactis NCDO 2118 (DSS +NCDO2118
group) orally for four consecutive days. Fresh total cul-
tures of NCDO2118 (bacteria plus supernatant at a sta-
tionary phase of growth) were prepared daily before being
offered to the mice. Because each mouse drank approxi-
mately 5 mL of culture per day (data not shown), the total
dose of bacteria per mouse was estimated to be 5×109
bacteria/day. Mice were sacrificed either at day 14
(immediately following the oral treatment) or after a
second DSS cycle (at day 21). The control groups of
mice received M17 or L. lactis alone. Throughout the
experimental period, all mice had unlimited access to
food. A schematic representation of the experimental
procedure is shown in Figure 2A.
Macroscopic and microscopic assessment of colitis
DSS-induced colitis was assessed macroscopically by
scoring three major clinical signs—weight loss, diarrhea,
and rectal bleeding—at day 14 and day 21 as described
by Cooper et al. [53]. Body weight loss was calculated as
the difference between the initial and actual weight.
Diarrhea was determined by assessing mucus/faecal ma-
terial adhering to anal fur and was confirmed by the
presence or absence of faecal pellet formation and con-
tinuous fluid faecal material in the colon. Rectal bleeding
was defined as diarrhea containing visible blood and
gross rectal bleeding. The three major clinical signs
(weight loss, diarrhea, and occult/gross bleeding) were
scored separately. The macroscopic score was calculated
from the score of the clinical signs using the following
formula: (weight loss score) + (diarrhea score) + (rectal
bleeding score). After the mice were sacrificed, their
spleens, mesenteric lymph nodes and colons were ex-
cised. Spleens and mesenteric lymph nodes were used
for cell population analysis. Colon samples were fixed
in formalin and processed for histological analysis.
Hematoxylin-eosin-stained sections were blindly scored
based on a previously described semi-quantitative scoringsystem [54]. The following features were graded: extent
of destruction of normal mucosal architecture (0: nor-
mal; 1, 2 and 3: mild, moderate and extensive damage,
respectively), presence and degree of cellular infiltration
(0: normal; 1, 2 and 3: mild, moderate and transmural
infiltration, respectively), extent of muscle thickening
(0: normal; 1, 2 and 3: mild, moderate and extensive
thickening, respectively), presence or absence of crypt
abscesses (0: absent; 1: present) and the presence or
absence of goblet cell depletion (0: absent; 1: present).
Scores for each feature were summed up to a maximum
possible score of 11.Colon tissue preparation and cytokine assay
Colon samples were weighed and homogenised in PBS
containing 0.05% (v/v) Tween-20, 0.1 mM phenyl-
methylsulphonyl fluoride, 0.1 mM benzethonium chloride,
10 mM EDTA and 20 KIU Aprotinin A using a tissue
homogeniser (100 mg tissue/ml buffer) [43]. Suspen-
sions were centrifuged at 12,000 g for 20 min at 4°C,
and the supernatants were collected for the cytokine
assay. The plates were coated with purified monoclonal
antibodies reactive for the cytokines IL-6, IL-12, IFN-γ,
IL-17, IL-10, TGF-β and TNF-α (BD-Pharmingen) over-
night at 4°C. On the following day, the wells were
washed, the supernatants were added and the plate was
incubated overnight at 4°C. On the third day, biotinyl-
ated monoclonal antibodies against the cytokines were
added, and the plates were incubated for 2 hours at
room temperature. Colour was developed at room
temperature with 100 μl/well of orthophenylenediamine
(1 mg/ml) and 0.04% (v/v) H2O2 substrate in sodium
citrate buffer. The reaction was interrupted by the
addition of 20 μl/well of 2 N H2SO4. The absorbance
was measured at 492 nm using a microplate reader
(BIO-RAD).Secretory IgA (sIgA) assay
The levels of sIgA were determined by ELISA. Briefly, 96-
well plates (NUNC) were coated with Ig goat anti-mouse
UNLB antibody in coating buffer (pH 9.6) overnight at 4°C.
The wells were washed and blocked with 200 μl of PBS
containing 0.25% casein for 1 h at room temperature. Sam-
ples were added to the plates and incubated for 1 h at 37°C.
The plates were then washed, peroxidase-streptavidin goat
anti-mouse IgA-HRP (Southern Biotechnology) diluted
1:10000 was added, and the plates were incubated for 1 h
at 37°C. Colour was developed at room temperature with
100 μl/well of orthophenylenediamine (1 mg/ml) (SIGMA)
and 0.04% H2O2 substrate in sodium citrate buffer. The
reaction was interrupted by the addition of 20 μl/well of
2 N H2SO4. The absorbance was measured at 492 nm
using an ELISA microplate reader (Bio-Rad).
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Fluorescein isothiocyanate-conjugated (FITC) mAbs against
CD69, CD25 and CD11c; phycoerythrin (PE)-conjugated
mAbs against CD45RB and CD11b; and biotinylated
antibodies against CD103 were utilised. Streptavidin-
Cy5-Chrome was purchased from BD Biosciences. The
biotinylated anti-human LAP (TGF-β) antibody was
purchased from R&D Systems. Surface staining was per-
formed according to standard procedures at density of
1×106 cells (isolated from the spleen or mesenteric
lymph nodes) per well. The samples were analysed in a
FACScan instrument (BD), and the results were ana-
lysed by FlowJo Software (Tree Star Inc.).
Statistical analysis
The results were expressed as the mean ± standard error
of the mean (SEM). Normal distribution of the samples
was confirmed by the Kolmogorov–Smirnov test. The
significance of differences among groups was determined
by Student’s t-test or analysis of variance (ANOVA)
(Tukey’s post test). Means were considered significantly
different when P < 0.05.
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